Healthcare & Life Sciences

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

A complex share buyback and reverse stock split reveal Havas's deeper strategy: shoring up its finances to invest in a new era of health communication.

A data breach at a risk management firm exposes sensitive data for thousands, raising urgent questions about industry security and accountability.

Your health plan is evolving beyond medical bills. Insurers are now funding doulas, food, and transport to tackle the root causes of poor health.

A top industrial firm offers a surprising blueprint for fixing healthcare's biggest challenges, from clinician burnout to supply chain woes.

A Chinese environmental giant and a Singaporean robotics upstart join forces. Can their automated solutions really clean up the world's dirtiest jobs?

A novel drug for alcohol use disorder gets key scientific backing. It promises the benefits of psychedelics with fewer risks, shaking up a $35B market.

After a painful restructuring, industrial manufacturer NN, Inc. is now exploring a sale. Is this the final step in its transformation or a capitulation?

PSH continues its multi-billion dollar share repurchase strategy to tackle its stubborn stock discount. What does this mean for the fund and its future targets?

Dialed Moods' new sea moss and shilajit gummies enter a booming market. But do the ancient ingredients and modern science justify the industry's latest rush?

PG&E's new grid tech does more than keep lights on; it's a vital upgrade for healthcare resilience, wildfire prevention, and safety in a changing climate.

New journalism awards tackle AI's risks and Indigenous health gaps, revealing how media innovation aims to build a healthier, more equitable Canada.

As the AI skills gap widens, a new framework aims to move companies from pilot purgatory to true adoption by training everyone, not just tech experts.

Fivetran's new Gartner status reveals a deeper industry shift: the race to build the unified data plumbing that will determine if we can trust AI.

A $2.4B deal for Alphawave IP and a revealing investor filing pull back the curtain on the high-stakes race to build the infrastructure for an AI world.

Recent product recalls reveal deep flaws in our safety systems. What can this teach us about regulating the complex world of medical AI before it's too late?

After years of delays, River Rock Capital Partners has taken over a stalled NC project, betting on unmet demand in one of the state's fastest-growing areas.

Subsense just raised $27M for a BCI delivered via nasal spray. It could democratize neurotech, but what's the cost to our identity and safety?

A new pediatric network is betting it can fix fragmented care with integrated tech and a focus on clinicians. Its latest target: Atlanta's crowded market.

The CRA's move to digital-first tax filing promises efficiency, but could it block vulnerable Canadians from the very benefits that support their health?